Menomune

Generic name:neisseria meningitidis group a polysaccharide antigen, a, neisseria meningitidis group c polysaccharide antigen, a, neisseria meningitidis group y polysaccharide antigen, a and neisseria meningitidis group w-135 polysaccharide antigen, a
Dosage form: injection
Drug class:Bacterial vaccines

Medically reviewed by Drugs.com. Last updated on Sep 21, 2021.

1. INDICATIONS AND USAGE

Menomune® – A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menomune – A/C/Y/W-135 vaccine is approved for use in persons 2 years of age and older.

Menomune – A/C/Y/W-135 vaccine is not indicated for the prevention of meningitis caused by microorganisms other than N. meningitidis serogroups A, C, Y, and W-135. Menomune – A/C/Y/W-135 vaccine is not indicated for treatment of meningococcal infections.

2. DOSAGE AND ADMINISTRATION

. Administration

The lyophilized vaccine should be a white or off-white color to a light beige color. The diluent used for reconstitution is a clear liquid.

Using a suitable size syringe, withdraw the supplied diluent (0.6 mL for single-dose presentation and 6.0 mL for multidose presentation) and inject into the vial containing the lyophilized vaccine. Swirl the vial until the vaccine is thoroughly dissolved. When reconstituted, the vaccine should be a clear, colorless liquid.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exist, the vaccine should not be administered.

Withdraw and administer a 0.5 mL dose of Menomune – A/C/Y/W-135 vaccine by subcutaneous injection.

Vaccine supplied in single dose vials should be used immediately after reconstitution.

Vaccine supplied in multidose vials may be...